# Attempt 003 — Claim-Backing Audit: medical/CONVERGENCE.md + MEDICAL_PROBLEMS.md

**Date**: 2026-04-15
**Phase**: Audit (cross-cutting, AUDIT_LOG.md queue)
**Scope**: medical/CONVERGENCE.md (158 lines) + MEDICAL_PROBLEMS.md
(84 lines) = cross-disease synthesis index.
**Standard**: math/ns_blowup/attempts/attempt_849_frobenius_ratio_gap.md
**Prior**: audit log fires 1–28.

## Executive verdict

Both are **master-index-class documents**. CONVERGENCE.md is the
cross-disease trial roadmap; MEDICAL_PROBLEMS.md is the 16-disease
inventory. They operate as entry points for different audiences
(clinician planning trials / researcher surveying scope).

Neither adds RED-level new concerns beyond those already audited.
Both reference and cross-link to the 7 top-tier docs identified in
fires 27–28.

**🔴 RED count**: 1 (meta-level — "Tregs + Mitochondria as universal
brakes" framing extends cross-disease unification beyond CVB; see
below)
**🟡 YELLOW count**: 5
**🟢 GREEN count**: 10

## RED findings

### R33 — MEDICAL_PROBLEMS.md L50 + CONVERGENCE.md L124–131 (universal-mechanism framing)

**The claim**:
> "Tregs are the universal brake. Mitochondria are the universal
> energy. Every disease involves either insufficient Treg
> suppression OR mitochondrial dysfunction (or both)." (MEDICAL_
> PROBLEMS.md L50)

> "All 14 diseases involve: NF-κB/TNF-α amplification; NLRP3
> inflammasome → IL-1β; Treg insufficiency … Gut dysbiosis; Bistable
> attractor dynamics" (CONVERGENCE.md L124–131)

**Why load-bearing**: this is the **cross-disease unifying thesis**
that justifies applying the protocol from T1DM to 15 other conditions.
If every disease genuinely reduces to these 5 shared mechanisms, the
protocol's broad application is mechanistically justified. If the
framing is over-selected (every disease mapped onto these 5 bins
because that's the lens the operator applies), the broad application
is framework-driven, not mechanism-driven.

**Concern**: same structural issue as R31 (physics K-framework) and
R32 (philosophy α/β/γ fork). "Every one of N items fits my N-bin
framework" where zero exceptions are documented is the
confirmation-bias-audit trigger. None of the 16 diseases is labeled
"does NOT involve Treg insufficiency" or "does NOT involve NLRP3
inflammasome activation" — they all map in.

**Counter-evidence in the corpus itself**: eczema/PROBLEM.md and
psoriasis/PROBLEM.md BOTH honestly label "Direct CVB connection:
WEAK/NONE" in their own PROBLEM.md (audited in fire 16). That's
honest per-disease. But the cross-disease synthesis in CONVERGENCE
pulls eczema/psoriasis back into the unified framework via Treg
insufficiency — a Category-2 "immune dysregulation co-beneficiary."
This is the kind of framing move that can absorb any inflammatory
disease without distinguishing signal from over-selection.

**Required fix**: add a CONVERGENCE.md subsection named
"Cross-Disease Framework Audit" that applies the same confirmation-
bias-audit discipline used in what_is_nothing/attempt_006 and in
physics/K_FRAMEWORK_AUDIT.md: (1) list diseases approached with the
Treg-NLRP3-framework and REJECTED as not-fitting (currently: zero);
(2) label whether the 3-category split was constructed BEFORE or
AFTER surveying the 16 diseases; (3) note the selection-bias risk
explicitly.

This is not a claim that the framing is wrong — it's a claim that
the framing's discipline requires a cross-disease audit paired with
the per-disease Phase 0 shape-checks that already exist.

## YELLOW findings

| # | File / line | Claim | Source gap |
|---|-------------|-------|------------|
| Y194 | CONVERGENCE L46 "Trehalose + LAMP2 κ_effective 0.15→0.40 testes, 0.22→0.50 CNS, 0.26→0.55 muscle" | Specific numbers per-organ — thread the ODD model file that produces these |
| Y195 | CONVERGENCE L48 "CoQ10/NAD+ added post-bioinformatics via MT-ND3 in 93 ME/CFS" | Matches me_cfs audit finding; GSE293840 accession threading already flagged |
| Y196 | CONVERGENCE L148 "WHM → IL-10 → FOXP3" as one of 4 Treg-restoring components | Once R22/R29 WHM fix propagates, this framing also needs adjustment — "WHM" now references the attenuated-NF-κB mechanism not lockdown |
| Y197 | MEDICAL_PROBLEMS per-disease attempt counts (L7–22) | Accurate as of write date; should note "as of 2026-04-15" since these numbers grow |
| Y198 | MEDICAL_PROBLEMS L45 "Infertility: the 'easy conceiver' phenotype overlaps almost perfectly with the 'CVB-resistant' phenotype" | Strong claim — "almost perfectly" needs either data or softening to "overlaps substantially" |

## GREEN findings

- **G200** CONVERGENCE hierarchical disease-tier structure (Prevention
  / Acute / Chronic) organizes 12 CVB diseases by intervention
  opportunity. Specific disease-to-tier mapping with rationale
  ("neonatal sepsis prevention → prevents ALL downstream").
- **G201** CONVERGENCE L28–43 Protocol Core table with per-component
  mechanism, cost/mo, and diseases addressed. $170/month total.
- **G202** CONVERGENCE L45–48 "Protocol update (post-bioinformatics)"
  section explicitly names the three changes: trehalose added
  (LAMP2), butyrate dose increased (FOXP1), CoQ10/NAD+ added
  (MT-ND3). Live document reflecting evidence updates.
- **G203** CONVERGENCE L50–65 disease-specific additions table.
  Each of 12+ diseases has a specific "Addition beyond core"
  entry with mechanism rationale.
- **G204** CONVERGENCE L67–90 Clinical Trial Roadmap ranked by
  Tier 1–4 feasibility. Tier 1 includes pericarditis RCT v3 (n=195,
  9 months), patient-zero T1DM n=1, post-meningitis ME/CFS
  prevention (n=144, 12-month primary endpoint). **Tier 1 items
  are 3 concrete trials not hypothetical interventions**.
- **G205** CONVERGENCE L74 "NEW Tier 1 — first campaign trial to
  PREVENT a chronic disease" — explicit novelty label. Post-
  meningitis ME/CFS prevention is positioned as prevention-not-
  treatment, a distinct claim class.
- **G206** CONVERGENCE L108–133 "Non-CVB Co-Beneficiaries"
  category split into Category 1/2/3 with **explicit labels**:
  Category 1 CVB-caused, Category 2 immune-dysregulation, Category
  3 optimization-responsive. Honest admission that eczema/psoriasis
  are NOT CVB-caused.
- **G207** CONVERGENCE L150–157 "Apremilast Bridge" — identifies
  one FDA-approved drug that bridges psoriasis (approved) → T1DM
  (off-label) → eczema (off-label) via the same NF-κB/PDE4
  mechanism. Cross-disease convergent-evidence argument.
- **G208** MEDICAL_PROBLEMS inventory table with per-disease
  column for status/phase/connection-detail — 16 rows, concise
  per-row. Master index for the campaign.
- **G209** MEDICAL_PROBLEMS L54–66 Method section references
  SIGMA_METHOD.md by name (which, per v3 discipline, is NOT
  checked into the repo). Compliance with working-dir separation.

## Recommended fixes (ordered)

1. **[P0]** CONVERGENCE add Cross-Disease Framework Audit subsection
   per R33 — apply the same confirmation-bias audit to the 3-
   category/5-mechanism framing that R31/R32 applied to K-framework
   and α/β/γ fork. This closes the meta-level concern that a unified
   mechanism across 16 diseases with zero rejections is a selection-
   bias trigger.
2. **[P1]** CONVERGENCE Y194: thread the ODD model file for the
   per-organ κ_effective numbers.
3. **[P2]** MEDICAL_PROBLEMS Y198: soften "almost perfectly" for
   infertility/CVB-resistant phenotype overlap, or cite specific
   data supporting the overlap.
4. **[P2]** Cross-update CONVERGENCE Y196 after the WHM sweep per
   fire 25 WHM_NFkB_CROSS_SUBDIR_FIX.md is executed — "WHM → IL-10
   → FOXP3" should reference attenuated NF-κB rather than lock.

## Non-audit observations

- **CONVERGENCE.md and MEDICAL_PROBLEMS.md complete the medical/
  top-level documentation triad** with CLINICAL_BRIEF.md
  (physician entry) + EVIDENCE_GRADES.md (claim grading) +
  FAILURE_MODES.md (pre-registered failures) + DRUG_SAFETY_MATRIX.md
  (interactions). Six top-level docs covering: entry point, evidence,
  safety, failures, trial roadmap, disease inventory. This is a
  complete clinical-campaign documentation set.
- **The R33 cross-disease framework concern extends the pattern**
  flagged in physics (R31 K-framework) and philosophy (R32 α/β/γ).
  Three major cross-subdir unifying patterns in the repo, all
  with framework audits now recommended (K-framework audit done
  in fire 23; α/β/γ audit done in fire 24; Treg-NLRP3 cross-disease
  audit recommended here in R33). If the operator wants to close
  all three framework audits in parallel, they now have paired
  recommendations.
- **8 medical/ top-level docs remain un-audited** (~1900 lines):
  MEDICAL/THEWALL (123), PRE_EXPOSURE_PREVENTION (117), PATIENT_
  ZERO_SCREENING (141), FOR_YOUR_DOCTOR (128), GEO_DATASET_CATALOG
  (178), CVB_VACCINE_STRATEGY (204), PREVENTION_STRATEGY (235),
  PATIENT_ZERO_TIMELINE (330 — contains R26 WHM reference), DISEASE_
  DATA_SUMMARY (404).

## Tag

003 (medical/ top-level). Audited CONVERGENCE.md + MEDICAL_PROBLEMS.md.
1 🔴 (R33: cross-disease Treg-NLRP3-framework unifies 16 diseases
with zero documented non-fits; same structural issue as R31 K-
framework and R32 α/β/γ fork; recommend Cross-Disease Framework Audit
subsection). 5 🟡 (per-organ κ_effective numbers need ODD-model
file, WHM framing dependency on pending fix). **10 🟢**: CONVERGENCE
hierarchical disease-tier structure, Protocol Core table with
per-component cost/mechanism, post-bioinformatics protocol update
explicitly listed, Tier 1 trial roadmap with 3 concrete trials
including "first campaign trial to PREVENT a chronic disease," honest
Category 2 ("Non-CVB Co-Beneficiaries") label for eczema/psoriasis,
Apremilast cross-disease bridge, MEDICAL_PROBLEMS 16-disease
inventory table with per-row status+phase, SIGMA_METHOD.md v3-
compliance via external reference. **Medical/ top-level now has 6
master documents auditable**: CLINICAL_BRIEF + EVIDENCE_GRADES +
DRUG_SAFETY_MATRIX + FAILURE_MODES + CONVERGENCE + MEDICAL_PROBLEMS
— a complete clinical-campaign documentation set. 8 remaining docs
(~1900 lines). Next fire: continue medical/ remaining / biology
attempts / WHM sweep.
